339 related articles for article (PubMed ID: 24146299)
1. Gadolinium and nephrogenic systemic fibrosis: an update.
Weller A; Barber JL; Olsen OE
Pediatr Nephrol; 2014 Oct; 29(10):1927-37. PubMed ID: 24146299
[TBL] [Abstract][Full Text] [Related]
2. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents.
Penfield JG
Pediatr Nephrol; 2008 Dec; 23(12):2121-9. PubMed ID: 18543004
[TBL] [Abstract][Full Text] [Related]
3. Nephrogenic systemic fibrosis.
Weinreb JC; Kuo PH
Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
[TBL] [Abstract][Full Text] [Related]
4. Gadolinium-associated nephrogenic systemic fibrosis.
Schlaudecker JD; Bernheisel CR
Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
[TBL] [Abstract][Full Text] [Related]
5. Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure.
Bernstein EJ; Schmidt-Lauber C; Kay J
Best Pract Res Clin Rheumatol; 2012 Aug; 26(4):489-503. PubMed ID: 23040363
[TBL] [Abstract][Full Text] [Related]
6. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
Idée JM; Port M; Dencausse A; Lancelot E; Corot C
Radiol Clin North Am; 2009 Sep; 47(5):855-69, vii. PubMed ID: 19744600
[TBL] [Abstract][Full Text] [Related]
7. Nephrogenic Systemic Fibrosis Manifesting a Decade After Exposure to Gadolinium.
Larson KN; Gagnon AL; Darling MD; Patterson JW; Cropley TG
JAMA Dermatol; 2015 Oct; 151(10):1117-20. PubMed ID: 26017458
[TBL] [Abstract][Full Text] [Related]
8. Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis.
Heverhagen JT; Krombach GA; Gizewski E
Rofo; 2014 Jul; 186(7):661-9. PubMed ID: 24477507
[TBL] [Abstract][Full Text] [Related]
9. Gadolinium-based contrast agents in children.
Rozenfeld MN; Podberesky DJ
Pediatr Radiol; 2018 Aug; 48(9):1188-1196. PubMed ID: 30078039
[TBL] [Abstract][Full Text] [Related]
10. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction.
Kay J
Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii66-9. PubMed ID: 19022818
[TBL] [Abstract][Full Text] [Related]
11. Gadolinium-Induced Fibrosis.
Todd DJ; Kay J
Annu Rev Med; 2016; 67():273-91. PubMed ID: 26768242
[TBL] [Abstract][Full Text] [Related]
12. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases.
Zou Z; Zhang HL; Roditi GH; Leiner T; Kucharczyk W; Prince MR
JACC Cardiovasc Imaging; 2011 Nov; 4(11):1206-16. PubMed ID: 22093272
[TBL] [Abstract][Full Text] [Related]
13. [Nephrogenic systemic fibrosis: a severe complication of use to gadolinium in patients with kidney failure].
Mundim JS; Lorena Sde C; Abensur H; Elias RM; Moysés RM; Castro MC; Romão Júnior JE
Rev Assoc Med Bras (1992); 2009; 55(2):220-5. PubMed ID: 19488662
[TBL] [Abstract][Full Text] [Related]
14. Nephrogenic systemic fibrosis: report of an additional case with granulomatous inflammation.
Wilford C; Fine JD; Boyd AS; Sanyal S; Abraham JL; Kantrow SM
Am J Dermatopathol; 2010 Feb; 32(1):71-5. PubMed ID: 19940755
[TBL] [Abstract][Full Text] [Related]
15. Nephrogenic systemic fibrosis and gadolinium-based contrast agents.
Abu-Alfa AK
Adv Chronic Kidney Dis; 2011 May; 18(3):188-98. PubMed ID: 21531325
[TBL] [Abstract][Full Text] [Related]
16. Pathomechanisms of nephrogenic systemic fibrosis: new insights.
Gupta A; Shamseddin MK; Khaira A
Clin Exp Dermatol; 2011 Oct; 36(7):763-8. PubMed ID: 21790732
[TBL] [Abstract][Full Text] [Related]
17. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update.
Idée JM; Fretellier N; Robic C; Corot C
Crit Rev Toxicol; 2014 Nov; 44(10):895-913. PubMed ID: 25257840
[TBL] [Abstract][Full Text] [Related]
18. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
Boyd AS; Sanyal S; Abraham JL
J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
[TBL] [Abstract][Full Text] [Related]
19. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents.
Kitajima K; Maeda T; Watanabe S; Ueno Y; Sugimura K
Int J Urol; 2012 Sep; 19(9):806-11. PubMed ID: 22571387
[TBL] [Abstract][Full Text] [Related]
20. [Causal relationship between the use of gadolinium based contrast media and nephrogenic systemic fibrosis].
Varela CU; Prieto-Rayo JC
Rev Med Chil; 2014 Dec; 142(12):1565-74. PubMed ID: 25693439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
